ROR2 and renal carcinoma: When looking at the clinical trials registered to date, there are two additional studies investigating the ROR2-specific CAR T cells in solid malignancies expressing ROR2 (NCT03960060) or, more specifically, ROR2-positive renal carcinomas (NCT03393936).